England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug Available - (Morningstar via NewsPoints Desk)

  • The NHS has elected to initiate a clinical study as an effort to provide access to a generic version of Gilead Sciences HIV drug Truvada, Morningstar reported Friday.

  • The NHS can use the generic drug, developed by Mylan, with infringing patents because drugs used in clinical studies are exempt from patent litigation under UK law.

  • In the study, the NHS will provide access to the therapy to as many as 10 000 people, with some experts suggesting the move could set a precedent in Europe.

  • "The unusual length, extent and nature of this 'implementation trial' may well set significant precedent for the unencumbered use of generics on the NHS," remarked Siva Thambisetty, associate professor in intellectual property law at the London School of Economics and Political Science.

  • Truvada and its generics are used in a number of global markets for HIV pre-exposure prophylaxis (PrEP).

  • "This is a good step forward," stated HIV activist Will Nutland, continuing "we've been waiting for years for PrEP to become more widely available."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.